<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03993210</url>
  </required_header>
  <id_info>
    <org_study_id>19-056</org_study_id>
    <nct_id>NCT03993210</nct_id>
  </id_info>
  <brief_title>The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids</brief_title>
  <official_title>The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to test new MRI methods called Magnetic Resonance Fingerprinting&#xD;
      and Q-space Trajectory Imaging in gynecological abnormalities. The purpose of this research&#xD;
      study is to evaluate if these new MRI methods can give additional information in&#xD;
      characterizing gynecological tumors compared with conventional MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnetic resonance imaging (MRI) is a safe and painless test that uses a magnetic field and&#xD;
      radio waves to produce detailed images of the body's organs and structures. This research is&#xD;
      being done to test new MRI methods called Magnetic Resonance Fingerprinting (MRF) and Q-space&#xD;
      Trajectory Imaging (QTI) in gynecological abnormalities. The purpose of this research study&#xD;
      is to evaluate if these new MRI methods can give additional information in characterizing&#xD;
      gynecological tumors compared with conventional MRI&#xD;
&#xD;
      In this research study, the investigators are:&#xD;
&#xD;
        -  Investigating the use of MR imaging in gynecological tumors on imaging quality and&#xD;
           comparison of tumor or fibroid structures and normal anatomy&#xD;
&#xD;
        -  Investigating whether new MRI methods could help in characterizing the tumor and give&#xD;
           information about the expected outcome&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Key personnel moving out&#xD;
  </why_stopped>
  <start_date type="Actual">September 18, 2019</start_date>
  <completion_date type="Actual">September 19, 2019</completion_date>
  <primary_completion_date type="Actual">September 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Feasible Imaging</measure>
    <time_frame>Day 1</time_frame>
    <description>Feasibility is determined by both A) having evaluable images in terms of quality according to radiology review and B) having a complete set of tumor metrics [MRF (T1 and T2 relaxation values) and QTI (total mean kurtosis MKT, microscopic anisotropy MKA, isotropic heterogeneity MK1, fractional anisotropy FA, microscopic fractional anisotropy µFA)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRF T1 Relaxation Value</measure>
    <time_frame>Day 1</time_frame>
    <description>T1 relaxation values (unit: milliseconds) will be extracted from regions-of-interest based on anatomical structures using MRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRF T2 Relaxation Value</measure>
    <time_frame>Day 1</time_frame>
    <description>T2 relaxation values (unit: milliseconds) will be extracted from regions-of-interest based on anatomical structures in using MRF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTI Total Mean Kurtosis</measure>
    <time_frame>Day 1</time_frame>
    <description>Total mean kurtosis evaluated by established methods using QTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTI Microscopic Anisotropy MKA</measure>
    <time_frame>Day 1</time_frame>
    <description>MKa (normalized variance due to anisotropic heterogeneity, unitless) will be extracted from regions-of-interest based on anatomical structures in using advanced diffusion weighted sequences with QTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTI Isotropic Heterogeneity MK1</measure>
    <time_frame>Day 1</time_frame>
    <description>Isotropic heterogeneity MK1 value evaluated by established methods using QTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTI Fractional Anisotropy FA</measure>
    <time_frame>Day 1</time_frame>
    <description>Fractional anisotropy FA value evaluated by established methods using QTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTI Microscopic Fractional Anisotropy µFA</measure>
    <time_frame>Day 1</time_frame>
    <description>Microscopic fractional anisotropy µFA value evaluated by established methods using QTI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Time from enrollment to death or last follow-up (censored) estimated using Kaplan-Meier methods</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Gynecologic Tumor</condition>
  <arm_group>
    <arm_group_label>GYN Cancer Cases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GYN Benign Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Fingerprinting (MRF)</intervention_name>
    <description>In MRF, multiple tissue properties are acquired simultaneously.</description>
    <arm_group_label>GYN Benign Controls</arm_group_label>
    <arm_group_label>GYN Cancer Cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q-space Trajectory Imaging (QTI)</intervention_name>
    <description>By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.</description>
    <arm_group_label>GYN Benign Controls</arm_group_label>
    <arm_group_label>GYN Cancer Cases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging Machine (MRI)</intervention_name>
    <description>MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.</description>
    <arm_group_label>GYN Benign Controls</arm_group_label>
    <arm_group_label>GYN Cancer Cases</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with suspected or histologically confirmed diagnosis of primary or&#xD;
             recurrent gynecological cancer including uterine endometrial, cervical, vaginal,&#xD;
             vulvar, ovarian, and smooth-muscle tumors undergoing routine clinical standard of care&#xD;
             pelvic MRI&#xD;
&#xD;
          -  Control subjects with benign fibroids undergoing routine clinical standard of care&#xD;
             pelvic MRI&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status of ≤ 2, based on treating physician's discretion (Appendix A)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to MRI identified by the MR procedure screening form, such as a&#xD;
             pacemaker, aneurysm clip, inner ear implant, neurostimulator, or other MR&#xD;
             non-compatible device or implant&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Non-english speaking subjects&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clare Tempany, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <results_first_submitted>September 22, 2020</results_first_submitted>
  <results_first_submitted_qc>November 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 2, 2020</results_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Clare Tempany</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gynecologic Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication.</ipd_time_frame>
    <ipd_access_criteria>BCH - Contact the Technology &amp; Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu BIDMC - Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu BWH - Contact the Partners Innovations team at http://www.partners.org/innovation DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu MGH - Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03993210/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03993210/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GYN Cancer Cases</title>
          <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
        </group>
        <group group_id="P2">
          <title>GYN Benign Controls</title>
          <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study closed due to PI departure.</population>
      <group_list>
        <group group_id="B1">
          <title>GYN Cancer Cases</title>
          <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
        </group>
        <group group_id="B2">
          <title>GYN Benign Controls</title>
          <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Feasible Imaging</title>
        <description>Feasibility is determined by both A) having evaluable images in terms of quality according to radiology review and B) having a complete set of tumor metrics [MRF (T1 and T2 relaxation values) and QTI (total mean kurtosis MKT, microscopic anisotropy MKA, isotropic heterogeneity MK1, fractional anisotropy FA, microscopic fractional anisotropy µFA)]</description>
        <time_frame>Day 1</time_frame>
        <population>No analysis was conducted because the PI left the institution. This lead to closure of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Feasible Imaging</title>
          <description>Feasibility is determined by both A) having evaluable images in terms of quality according to radiology review and B) having a complete set of tumor metrics [MRF (T1 and T2 relaxation values) and QTI (total mean kurtosis MKT, microscopic anisotropy MKA, isotropic heterogeneity MK1, fractional anisotropy FA, microscopic fractional anisotropy µFA)]</description>
          <population>No analysis was conducted because the PI left the institution. This lead to closure of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRF T1 Relaxation Value</title>
        <description>T1 relaxation values (unit: milliseconds) will be extracted from regions-of-interest based on anatomical structures using MRF.</description>
        <time_frame>Day 1</time_frame>
        <population>PI left the country, resulting in study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic MRI along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>-Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic MRI along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>MRF T1 Relaxation Value</title>
          <description>T1 relaxation values (unit: milliseconds) will be extracted from regions-of-interest based on anatomical structures using MRF.</description>
          <population>PI left the country, resulting in study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRF T2 Relaxation Value</title>
        <description>T2 relaxation values (unit: milliseconds) will be extracted from regions-of-interest based on anatomical structures in using MRF.</description>
        <time_frame>Day 1</time_frame>
        <population>PI left the country, resulting in study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.&#xD;
Magnetic Resonance Fingerprinting (MRF): In MRF, multiple tissue properties are acquired simultaneously.&#xD;
Q-space Trajectory Imaging (QTI): By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.&#xD;
Magnetic Resonance Imaging Machine (MRI): MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.&#xD;
Magnetic Resonance Fingerprinting (MRF): In MRF, multiple tissue properties are acquired simultaneously.&#xD;
Q-space Trajectory Imaging (QTI): By using q-space trajectory encoding and a diffusion tensor distribution model, QTI improves the discrimination of diffusivity, shape, and orientation of diffusion microenvironments and therefore carries major potential for imaging the tumor microenvironment.&#xD;
Magnetic Resonance Imaging Machine (MRI): MRI is routinely used in gynecologic malignancies for its ability to depict the extent of disease at diagnosis providing guidance in staging and treatment planning.</description>
          </group>
        </group_list>
        <measure>
          <title>MRF T2 Relaxation Value</title>
          <description>T2 relaxation values (unit: milliseconds) will be extracted from regions-of-interest based on anatomical structures in using MRF.</description>
          <population>PI left the country, resulting in study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTI Total Mean Kurtosis</title>
        <description>Total mean kurtosis evaluated by established methods using QTI</description>
        <time_frame>Day 1</time_frame>
        <population>PI left the country, resulting in study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>QTI Total Mean Kurtosis</title>
          <description>Total mean kurtosis evaluated by established methods using QTI</description>
          <population>PI left the country, resulting in study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTI Microscopic Anisotropy MKA</title>
        <description>MKa (normalized variance due to anisotropic heterogeneity, unitless) will be extracted from regions-of-interest based on anatomical structures in using advanced diffusion weighted sequences with QTI</description>
        <time_frame>Day 1</time_frame>
        <population>PI left the country, resulting in study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>QTI Microscopic Anisotropy MKA</title>
          <description>MKa (normalized variance due to anisotropic heterogeneity, unitless) will be extracted from regions-of-interest based on anatomical structures in using advanced diffusion weighted sequences with QTI</description>
          <population>PI left the country, resulting in study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTI Isotropic Heterogeneity MK1</title>
        <description>Isotropic heterogeneity MK1 value evaluated by established methods using QTI</description>
        <time_frame>Day 1</time_frame>
        <population>PI left the country, resulting in study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>QTI Isotropic Heterogeneity MK1</title>
          <description>Isotropic heterogeneity MK1 value evaluated by established methods using QTI</description>
          <population>PI left the country, resulting in study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTI Fractional Anisotropy FA</title>
        <description>Fractional anisotropy FA value evaluated by established methods using QTI</description>
        <time_frame>Day 1</time_frame>
        <population>PI left the country, resulting in study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>QTI Fractional Anisotropy FA</title>
          <description>Fractional anisotropy FA value evaluated by established methods using QTI</description>
          <population>PI left the country, resulting in study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTI Microscopic Fractional Anisotropy µFA</title>
        <description>Microscopic fractional anisotropy µFA value evaluated by established methods using QTI</description>
        <time_frame>Day 1</time_frame>
        <population>PI left the country, resulting in study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>QTI Microscopic Fractional Anisotropy µFA</title>
          <description>Microscopic fractional anisotropy µFA value evaluated by established methods using QTI</description>
          <population>PI left the country, resulting in study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Overall Survival</title>
        <description>Time from enrollment to death or last follow-up (censored) estimated using Kaplan-Meier methods</description>
        <time_frame>Up to 4 years</time_frame>
        <population>PI left the country, resulting in study closure.</population>
        <group_list>
          <group group_id="O1">
            <title>GYN Cancer Cases</title>
            <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
          <group group_id="O2">
            <title>GYN Benign Controls</title>
            <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival</title>
          <description>Time from enrollment to death or last follow-up (censored) estimated using Kaplan-Meier methods</description>
          <population>PI left the country, resulting in study closure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>No time frame.</time_frame>
      <desc>PI left the country, resulting in study closure. Adverse events were not assessed in this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>GYN Cancer Cases</title>
          <description>Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
        </group>
        <group group_id="E2">
          <title>GYN Benign Controls</title>
          <description>Benign gynecological (GYN) fibroids.&#xD;
Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was closed when the Principal Investigator left the country to begin work in Finland. One subject was scanned, but never analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clare Tempany</name_or_title>
      <organization>DFCI</organization>
      <phone>617-732-7858</phone>
      <email>ctempany@bwh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

